News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.

Featured news

The FDA grants lecanemab accelerated approval

Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.

Published date:

Gantenerumab fails to meet primary goal

In a press release, Roche confirmed that the Phase 3 GRADUATE studies for gantenerumab did not meet their primary goal of slowing clinical decline in people with early Alzheimer’s disease.

Published date:

Values20 launches communiqué in preparation for G20

The communiqué calls on the G20 to lead the way in being truly values-driven for global impact and to operate in an environment where there is an agreement on shared values, clarity on unique values across nations, understanding of the values of difference and more.

Published date:

WISH launches new palliative care report with ADI

‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).

Published date: